Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eloxx Pharmaceuticals Inc (ELOX) has shared an update.
Eloxx Pharmaceuticals has initiated a stock option repricing for their CEO’s eligible options under the 2018 Equity Incentive Plan, reducing the exercise price to $0.90, aligning with the closing stock price on March 25, 2024. This move affects both vested and unvested options, significantly lowering the weighted average exercise price from $37.47 for nearly 200,000 shares owned by CEO Sumit Aggarwal, potentially making it more attractive for investment and retention purposes.
See more insights into ELOX stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money